CD8A and neoplasm: CyTOF and scRNAseq analysis of the TME revealed that ceralasertib reshapes the TME by decreasing the exhausted CD8+ T-cell phenotype and reducing monocytic myeloid derived suppressor cells (M-MDSCs) and tumor-associated macrophages (TAMs).